Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
This 10-week study assessed the efficacy of atomoxetine in combination with psychoeducation compared to placebo and psychoeducation in the improvement of Quality of Life in Swedish stimulant-naive children and adolescents with attention deficit/hyperactivity disorder. A total of 99 patients were treated with atomoxetine (49 patients) or placebo (50 patients) for 10 weeks and assessed regarding broader areas of functioning using the Quality of Life measures Child Health and Illness Profile-Child Edition (CHIP-CE), Family Strain Index [FSI; equivalent to the Family Burden of Illness Module used in the study], Appraisal of Stress in Child-Rearing (ASCR), Five to fifteen (FTF), "I think I am" ("Jag tycker jag är"), and Children's Depression Rating Scale-Revised (CDRS-R) before and after the active treatment phase. Simultaneously, the patients' parents participated in a 4-session psychoeducation program. A statistically significant difference in favor of atomoxetine was seen in the improvement from baseline to study endpoint for the CHIP-CE domains "Achievement" and "Risk avoidance", for the FSI total score, for the ASCR section (I) domain "Child as a burden", for all FTF domains except for "Language and Speech", and for the CDRS-R total score. No difference between treatment groups was observed in the patient-assessed evaluation of self-esteem using the "I think I am" scale. Atomoxetine combined with psychoeducation had a positive effect on various everyday coping abilities of the patients as well as their families during 10 weeks of treatment, whereas the patients' self-image and the parents' image of the climate in the family were not significantly improved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 1×
“Perwien [29] summarized the results from three placebo-controlled atomoxetine studies with a duration of 7– 8 weeks [23, 24, 41] including 403 patients on atomoxetine and 181 on placebo.”
BackgroundEvidence-based pharmacotherapy for attention-deficit hyperactivity disorder
Biederman, J., Spencer, T., & Wilens, T. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003973 · Cited by 253 · cited 1×
“The efficacy of stimulants and atomoxetine, a nonstimulant first licensed in the US in 2002, has been well documented in clinical trials [3, 6 ]. During the recent years, an increasing amount of research has investigated the health-related quality of life (HRQL) and the functional impairments of the daily life of pati…”
BackgroundADHD and language impairment: A study of the parent questionnaire FTF (Five to Fifteen)
Bruce, B., Thernlund, G., & Nettelbladt, U. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0508-9 · Cited by 180
Self-citationWeiss, M., Tannock, R., Kratochvil, C., Dunn, D., Velez-Borras, J., Thomason, C., Tamura, R., Kelsey, D., Stevens, L., & Allen, A. J. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000163280.47221.c9 · Cited by 147 · cited 1×
“Perwien [29] summarized the results from three placebo-controlled atomoxetine studies with a duration of 7– 8 weeks [23, 24, 41] including 403 patients on atomoxetine and 181 on placebo.”
BackgroundMATZA, L. S., RENTZ, A. M., SECNIK, K., SWENSEN, A. R., REVICKI, D. A., MICHELSON, D., SPENCER, T., NEWCORN, J. H., & KRATOCHVIL, C. J. (2004) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200406000-00005 · Cited by 119 · cited 1×
“Previous research has indicated that ADHD is associated with a range of deficits in various areas of functioning such as low self-esteem, emotional liability, academic underachievement, disturbed peer relations, and family interaction [4, 22, 26].”
BackgroundPrasad, S., Harpin, V., Poole, L., Zeitlin, H., Jamdar, S., Puvanendran, K., & on behalf of the SUNBEAM Study Group (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167309 · Cited by 97
Perwien, A. R., Kratochvil, C. J., Faries, D. E., Vaughan, B. S., Spencer, T., & Brown, R. T. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.713 · Cited by 74 · cited 1×
“In an open-label long-term study, 912 patients started treatment on atomoxetine, and patients who continued the study were evaluated according to CHQ after an ‘‘acute’’ phase of 10 weeks, and at 6 and 24 months [30].”
BackgroundSvanborg, P., Thernlund, G., Gustafsson, P. A., Hägglöf, B., Poole, L., & Kadesjö, B. (2009) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-008-0725-5 · Cited by 71
Self-citationSelf-Report of Attention Deficit and Hyperactivity Disorder in Adolescents
Danckaerts, M., Heptinstall, E., Chadwick, O., & Taylor, E. (1999) · Psychopathology · doi:10.1159/000029071 · Cited by 47
Cited by
Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166
Jonsson, U., Alaie, I., Löfgren Wilteus, A., Zander, E., Marschik, P. B., Coghill, D., & Bölte, S. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12645 · Cited by 164
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“Response to ATX after previous exposure to other treatments, or in treatment-naı̈ve patients 20 [14, 17, 53, 58, 68, 96, 100, 102, 106, 120, 121, 126–134]”
BackgroundInfluentialCoghill, D. (2010) · CNS Drugs · doi:10.2165/11537450-000000000-00000 · Cited by 103
Toward Quality Care in ADHD: Defining the Goals of Treatment
Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V. (2015) · Journal of Attention Disorders · doi:10.1177/1087054712473835 · Cited by 33
Metadata
- Authors
- Svanborg, P., Thernlund, G., Gustafsson, P. A., Hägglöf, B., Schacht, A., & Kadesjö, B.
- Venue
- European Child & Adolescent Psychiatry
- Published
- 2009-05-23
- Volume
- 18
- Issue
- 12
- Pages
- 725-735
- ISSN
- 1018-8827 (ISSN-L)
- 1435-165X
- OpenAlex
- W2042184165
- Cited by
- 51
- References
- 10
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.